That was a follow up to this analyst upgrade to Overweight and $17.00 per share ZYNE PPS target. ZYNE upgraded to $17.00. Look for more of these. UPDATE: Cantor Fitzgerald Upgrades Zynerba Pharmaceuticals (ZYNE) to Overweight October 2, 2017 5:55 AM
(Updated - October 2, 2017 6:54 AM EDT)
(updated to add analyst comment)
Cantor Fitzgerald upgraded Zynerba Pharmaceuticals (NASDAQ: ZYNE) from Neutral to Overweight with a price target of $17.00 (from $4.00).
Analyst Elemer Piros cites the phase 2a data in Fragile X syndrome noting encouragement from the potential for ZYN002 in treating the disease. The analyst sees upside catalysts from additional regulatory clarity on late-stage development which is slated for 2018.
For an analyst ratings summary and ratings history on Zynerba Pharmaceuticals click here. For more ratings news on Zynerba Pharmaceuticals click here.